What question did this study set out to answer?

To evaluate the risk of suicidal behavior associated with GLP-1 RA medications.

FDA requests removal of suicide warnings from two GLP‐1 labels

View Full Paper

Ask AI

Bookmark

FDA evaluates GLP-1 medications and finds no increased risk of suicidal behaviors, suggesting manufacturers update labels.

To evaluate the risk of suicidal behavior associated with GLP-1 RA medications.
FDA analysis of existing data on GLP-1 RA medications
Review of safety information regarding suicidal behavior
Issuance of a letter to manufacturers for label update
FDA did not find increased risk of suicidal ideation or behavior with GLP-1 RA medications.
Request for removal of suicide-related warnings from product labels.

A 2026 study studied this question.

View Full Paper

Ask AI

Bookmark